Table I.
Summary of studies of G719X responses to 1G-TKIs.a
| Study | Mutation | TKI | Total | Response | RR/% | Sensitivity | Ref. |
|---|---|---|---|---|---|---|---|
| Lynch 2004 | G719C | G | 1 | 1 | 100 | Sensitive | 23 |
| Han 2005 | G719A | G | 2 | 1 | 50 | Intermediate | 24 |
| Takano 2005 | G719X | G | 2 | 1 | 50 | Intermediate | 25 |
| Eberhard 2005 | G719A | E | 1 | 0 | 0 | Resistant | 26 |
| Janne 2006 | G719C | G | 1 | 1 | 100 | Sensitive | 27 |
| Ichihara 2007 | G719X | G | 1 | 0 | 0 | Resistant | 28 |
| Pallis 2007 | G719D | G | 1 | 0 | 0 | Resistant | 29 |
| Sequist 2008 | G719A | G | 1 | 0 | 0 | Resistant | 30 |
| Wu 2008 | G719A | E/G | 2 | 1 | 50 | Intermediate | 31 |
| Wu 2011 | G719X | E/G | 8 | 4 | 50 | Intermediate | 32 |
| De Pas 2011 | G719S | E | 1 | 1 | 100 | Sensitive | 33 |
| Takahashi 2012 | G719A | G | 1 | 0 | 0 | Resistant | 34 |
| Lee 2013 | G719A | E | 1 | 0 | 0 | Resistant | 35 |
| Umekawa 2013 | G719A | E | 1 | 0 | 0 | Resistant | 36 |
| Locatelli-Sanchez 2013 | G719A | E/G | 1 | 1 | 0 | Resistant | 37 |
| Keam 2014 | G719A | G | 1 | 0 | 0 | Resistant | 38 |
| Beau-Faller 2014 | G719X | E/G | 10 | 1 | 10 | Resistant | 18 |
| Guan 2014 | G719A | E | 1 | 0 | 0 | Resistant | 39 |
| Watanabe 2014 | G719X | G | 3 | 0 | 0 | Resistant | 40 |
| Fukihara 2014 | G719A | E/G | 4 | 1 | 25 | Intermediate | 41 |
| Chiu 2015 | G719X | E/G | 76 | 28 | 36.8 | Intermediate | 42 |
| Xu 2016 | G719X | E/G/I | 14 | 6 | 42.9 | Intermediate | 43 |
| Total | 134 | 47 | 35.1 | Intermediate |
a
1G TKIs, 1st generation EGFR-TKIs mainly refers to gefitinib, erlotinib and icotinib. Data were extracted from corresponding studies. G, gefitinib; E, erlotinib; I, icotinib; RR, response rate. Sensitivity cut-off values: ≥0 RR<25%, resistant; ≥25% RR <75%, intermediately sensitive; ≥75% RR ≤100%, sensitive.